MoonLake Immunotherapeutics (MLTX) — Financial statements
Income statement, balance sheet, and cash flow for MoonLake Immunotherapeutics — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 3 | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | |
| Gross Profit | -3 | 0.00 | 0.00 | 0.00↑100.0% | -0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 203↑79.9% | 113↑254.6% | 32↓24.4% | 42↑18.4% | 36 | |
| General & Administrative Expenses | 42↑38.4% | 30↑35.8% | 22↓3.0% | 23 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 42↑38.4% | 30↑35.8% | 22↓3.0% | 23↑27.5% | 18 | |
| Other Expenses | -3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 242↑69.3% | 143↑164.4% | 54↓16.8% | 65↑21.4% | 54 | |
| Total Costs & Expenses | 245↑71.1% | 143↑164.4% | 54↓16.8% | 65↑21.4% | 54 | |
| Operating Results | ||||||
| Operating Income | -245↓71.1% | -143↓164.4% | -54↑16.8% | -65↓21.4% | -54 | |
| Depreciation & Amortization | 3↑88.9% | 1↑273.9% | 0.37↑124.7% | 0.16↑3214.9% | 0.00 | |
| EBITDA | -220↓55.1% | -142↓163.6% | -54↑17.2% | -65↓21.0% | -54 | |
| EBIT | -222↓55.5% | -143↓164.4% | -54↑16.8% | -65↓21.3% | -54 | |
| Interest & Other Income | ||||||
| Net Interest Income | -7 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 7 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -22 | 0.00 | 0.00 | 0.00↓100.0% | 0.06 | |
| Other Income / Expenses | 15↓31.7% | 22↑118.3% | 10↑1613.3% | 0.59↑1056.8% | -0.06 | |
| Income Before Tax | -230↓89.9% | -121↓175.0% | -44↑31.8% | -64↓20.2% | -54 | |
| Income Tax Expense | 0.61↑116.5% | 0.28↑199.0% | 0.09↑159.6% | 0.04↑664.8% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -230↓90.0% | -121↓175.1% | -44↑31.7% | -65↓20.2% | -54 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -227↓91.1% | -119↓230.3% | -36↑27.9% | -50↑6.8% | -54 | |
| Bottom-Line Net Income | -227↓91.1% | -119↓230.3% | -36↑27.9% | -50↑6.8% | -54 | |
| EPS (Basic) | -3.53↓86.8% | -1.89↓158.9% | -0.73↑66.8% | -2.20↓51.7% | -1.45 | |
| EPS (Diluted) | -3.53↓86.8% | -1.89↓158.9% | -0.73↑66.8% | -2.20↓51.7% | -1.45 | |
| Weighted Average Shares | 64↑2.5% | 63↑28.0% | 49↑67.3% | 29↓20.5% | 37 | |
| Weighted Average Diluted Shares | 64↑2.5% | 63↑28.0% | 49↑67.3% | 29↓20.5% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.